Cationic nanoemulsions bearing ciprofloxacin surf-plexes enhances its therapeutic efficacy in conditions of E. coli induced peritonitis and sepsis

Pharm Res. 2014 Oct;31(10):2630-42. doi: 10.1007/s11095-014-1360-0. Epub 2014 Apr 17.

Abstract

Purpose: Chitosan (CH) coated ciprofloxacin-sodium deoxycholate surfplex (CFn-SDC) loaded nanoemulsion (LE-CH-CFn-SDC) developed in order to improve tissue penetration of the CFn as well as to mop up the endotoxin (Lipopolysaccharides or LPS) released from bacteria during antibiotic treatment.

Methods: Size and zeta potential was evaluated for nanoemulsions prepared by high-speed homogenization and sonication. Drug analysis in samples was done by HPLC equipped with fluorescence detector. All formulations were evaluated for any change in LPS induced NO and TNF-α release and ROS generation in J774 macrophages. The formulations were also evaluated for in-vitro killing efficiency on E-Coli. The efficacy of formulations in terms of survival and pharmacokinetics and inhibition of induction of cytokines was carried out in E-coli induced peritonitis model in rats. LE-CH-CFn-SDC interacted with LPS both by electrostatic and hydrophobic interactions.

Results: LE-CH-CFn-SDC resulted in reduction of endotoxin release and MIC values for E. coli. LE-CH-CFn-SDC also reduced NO and TNF-α as well as ROS generation by reducing the uptake of LPS in J774 macrophages. LE-CH-CFn-SDC improved CFn pharmacokinetics and tissue distribution, by reducing the bacterial burden, LPS and cytokines (TNF-α and IL-6) thereby improving survival in a rat model of E. coli induced peritonitis.

Conclusion: In conclusion, this work highlights the effectiveness of the chitosan-coated nanoemulsion as intracorporeal approach for therapeutic intervention of E. coli induced peritonitis as well as in sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use
  • Cations
  • Chitosan / chemistry
  • Ciprofloxacin / administration & dosage*
  • Ciprofloxacin / pharmacokinetics
  • Ciprofloxacin / therapeutic use
  • Deoxycholic Acid / chemistry
  • Drug Carriers / chemistry*
  • Emulsions
  • Escherichia coli / drug effects
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / microbiology
  • Lipopolysaccharides / metabolism
  • Microbial Sensitivity Tests
  • Nanostructures / chemistry*
  • Particle Size
  • Peritonitis / drug therapy*
  • Peritonitis / immunology
  • Peritonitis / microbiology
  • Rats, Wistar
  • Sepsis / drug therapy*
  • Sepsis / immunology
  • Sepsis / microbiology
  • Technology, Pharmaceutical / methods

Substances

  • Anti-Bacterial Agents
  • Cations
  • Drug Carriers
  • Emulsions
  • Lipopolysaccharides
  • lipopolysaccharide, E coli O55-B5
  • Deoxycholic Acid
  • Ciprofloxacin
  • Chitosan